Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Environmental Protection Agency [EPA-HQ-OPPT-2021-0146; FRL-8682-09-OCSPP]
 AGENCY: Environmental Protection Agency (EPA).
 ACTION: Notice.
 SUMMARY: The Toxic Substances Control Act (TSCA) requires the Environmental Protection Agency (EPA) to publish in the 
                        **Federal Register**
                         a statement of its findings after its review of certain TSCA notices when EPA makes a finding that a new chemical substance or significant new use is not likely to present an unreasonable risk of injury to health or the environment. Such statements apply to premanufacture notices (PMNs), microbial commercial activity notices (MCANs), and significant new use notices (SNUNs) submitted to EPA under TSCA. This document presents statements of findings made by EPA on such submissions during the period from December 1, 2021 to December 31, 2021.
 FOR FURTHER INFORMATION CONTACT: *For technical information contact:*
                         Rebecca Edelstein, Chemical Control Division (7405M), Office of Pollution Prevention and Toxics, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460-0001; telephone number: 202-564-1667 email address: 
                        *Edelstein.rebecca@epa.gov.* *For general information contact:*
                         The TSCA-Hotline, ABVI-Goodwill, 422 South Clinton Ave., Rochester, NY 14620; telephone number: (202) 554-1404; email address: 
                        *TSCA-Hotline@epa.gov.*


SUPPLEMENTARY INFORMATION: I. General Information A. Does this action apply to me? This action is directed to the public in general. As such, the Agency has not attempted to describe the specific entities that this action may apply to. Although others may be affected, this action applies directly to the submitters of the PMNs addressed in this action. B. How can I get copies of this document and other related information? The docket for this action, identified by docket identification (ID) number EPA-HQ-OPPT-2021-0146, is available online at 
                    *http://www.regulations.gov*
                     or at the Office of Pollution Prevention and Toxics Docket (OPPT Docket), Environmental Protection Agency Docket Center (EPA/DC), West William Jefferson Clinton Bldg., Rm. 3334, 1301 Constitution Ave. NW, Washington, DC. The Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Public Reading Room is (202) 566-1744, and the telephone number for the OPPT Docket is (202) 566-0280. Due to the public health concerns related to COVID-19, the EPA Docket Center (EPA/DC) and Reading Room is opened to visitors by appointment only. For the latest status information on EPA/DC services and docket access, visit 
                    *https://www.epa.gov/​dockets.* II. What action is the Agency taking? This document lists the statements of findings made by EPA after review of notices submitted under TSCA section 5(a) that certain new chemical substances or significant new uses are not likely to present an unreasonable risk of injury to health or the environment. This document presents statements of findings made by EPA during the period from December 1, 2021 to December 31, 2021. III. What is the Agency's authority for taking this action? TSCA section 5(a)(3) requires EPA to review a TSCA section 5(a) notice and make one of the following specific findings: ○ The chemical substance or significant new use presents an unreasonable risk of injury to health or the environment; ○ The information available to EPA is insufficient to permit a reasoned evaluation of the health and environmental effects of the chemical substance or significant new use; ○ The information available to EPA is insufficient to permit a reasoned evaluation of the health and environmental effects and the chemical substance or significant new use may present an unreasonable risk of injury to health or the environment; ○ The chemical substance is or will be produced in substantial quantities, and such substance either enters or may reasonably be anticipated to enter the environment in substantial quantities or there is or may be significant or substantial human exposure to the substance; or ○ The chemical substance or significant new use is not likely to present an unreasonable risk of injury to health or the environment. Unreasonable risk findings must be made without consideration of costs or other non-risk factors, including an unreasonable risk to a potentially 
                    ( print page 4230)
                    exposed or susceptible subpopulation identified as relevant under the conditions of use. The term “conditions of use” is defined in TSCA section 3 to mean “the circumstances, as determined by the Administrator, under which a chemical substance is intended, known, or reasonably foreseen to be manufactured, processed, distributed in commerce, used, or disposed of.” EPA is required under TSCA section 5(g) to publish in the 
                    **Federal Register**
                     a statement of its findings after its review of a TSCA section 5(a) notice when EPA makes a finding that a new chemical substance or significant new use is not likely to present an unreasonable risk of injury to health or the environment. Such statements apply to PMNs, MCANs, and SNUNs submitted to EPA under TSCA section 5. Anyone who plans to manufacture (which includes import) a new chemical substance for a non-exempt commercial purpose and any manufacturer or processor wishing to engage in a use of a chemical substance designated by EPA as a significant new use must submit a notice to EPA at least 90 days before commencing manufacture of the new chemical substance or before engaging in the significant new use. The submitter of a notice to EPA for which EPA has made a finding of “not likely to present an unreasonable risk of injury to health or the environment” may commence manufacture of the chemical substance or manufacture or processing for the significant new use notwithstanding any remaining portion of the applicable review period. IV. What are the statements of administrator Findings under TSCA section 5(a)(3)(C)? In this unit, EPA provides the following information (to the extent that such information is not claimed as Confidential Business Information (CBI)) on the PMNs, MCANs and SNUNs for which, during this period, EPA has made findings under TSCA section 5(a)(3)(C) that the new chemical substances or significant new uses are not likely to present an unreasonable risk of injury to health or the environment: ○ EPA case number assigned to the TSCA section 5(a) notice. ○ Chemical identity (generic name if the specific name is claimed as CBI). ○ Website link to EPA's decision document describing the basis of the “not likely to present an unreasonable risk” finding made by EPA under TSCA section 5(a)(3)(C). EPA case No.
Chemical identity
Website linkP-18-0348
Ethanol, 2,2'-[1,4-phenylenebis(oxy)]bis-, polymer with 1,6-diisocyanatohexane and .alpha.-hydro-.omega.-hydroxypoly(oxy-1,4-butanediyl) (specific)
*https://www.epa.gov/​system/​files/​documents/​2022-01/​p-18-0348_​determination_​non-cbi_​final.pdf*.P-20-0018; P-20-0019; P-20-0020; P-20-0021
P-20-0018, P-20-0019, P-20-0020: Fatty acid dimers, polymers with glycerol and triglycerides (generic) P-20-0021: Fatty acid dimers, polymers with glycerol and fatty acids (generic)
*https://www.epa.gov/​system/​files/​documents/​2022-01/​p-20-0018-0021_​determination_​non-cbi_​final.pdf*.P-21-0120
2-Alkenoic acid, 2-alkyl-, 2-hydroxyalkyl ester, homopolymer, ester with N-[3-[(carboxyamino)alkyl]-3,5,5- trialkylcycloalkyl]carbamic acid mono [2-(2-alkoxyethoxy)alkyl] ester, N-[3-[(carboxyamino)alkyl]-3,5,5- trialkylcycloalkyl] carbamic acid mono [2-(dialkylamino) alkyl] ester and 2-oxepanone polymer with tetrahydro- 2H-pyran-2-one 2-alkylhexyl ester N-[3-(carboxyamino)alkyl phenyl] carbamate, 1,1-dialkylpropyl 2-alkylhexaneperoxoate—initiated (generic)
*https://www.epa.gov/​system/​files/​documents/​2022-01/​p-21-0120_​determination_​non-cbi_​final.pdf*.P-21-0135
Alkenoic acid, allyl-, (dialkylamino)alkyl ester, polymer with dialkyl-alkylene-alkanediyl)bis[carbomoncycle], alkylalkyl alkyl-alkenoate and alkanediol mono(2-alkyl-alkenoate), diazenediyl)bis[2-alkylalkanenitrile]-initiated, (generic)
*https://www.epa.gov/​system/​files/​documents/​2022-01/​p-21-0135_​determination_​non-cbi_​final.pdf*.P-21-0186; P-21-0187
glycerin, alkoxylated alkyl acid esters (generic)
*https://www.epa.gov/​system/​files/​documents/​2022-01/​p-21-0186-0187_​determination_​non-cbi_​final.pdf*.
 *Authority:*15 U.S.C. 2601 
                    *et seq.* Dated: January 24, 2022. Madison Le, Director, New Chemicals Division, Office of Pollution Prevention and Toxics.


[FR Doc. 2022-01647 Filed 1-26-22; 8:45 am] BILLING CODE 6560-50-P